The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.

Lantern Pharma Newsletter March 2023

The March 2023 edition of The Spark features the latest company updates including:

  • The Phase 2 Harmonic™ Trial Activates 5th Trial Site and Secures 1st Consented Patient
  • Lantern has Completed LP-184’s IND Enabling Studies & Phase 1A Trial Launch Targeted for Q2 2023
  • Starlight Therapeutics Launched to Advance LP-184’s Clinical Development Exclusively for CNS & Brain Cancers
  • Lantern and TTC Oncology Ink New AI-Driven Collaboration in Breast Cancer
  • Future RADR® Roadmap to Focus on the Development of Antibody Drug Conjugates
  • Learn More About Synthetic Lethality - The Unique Mechanism Behind Several of Lantern’s Drug Candidates
  • In Case You Missed It: A Replay of our Q4 2022 Earnings Call Is Now Available